Acquisitions And GrowthAdding Emraclidine to the model is expected to boost Abbvie’s portfolio, especially with the upcoming schizophrenia trial data.
Clinical Trial ResultsAbbVie released positive topline efficacy and encouraging safety results from tavapadon’s fixed-dose monotherapy trial for early Parkinson’s Disease.
Financial PerformanceHigher sales for Rinvoq, Skyrizi, Vraylar, and Venclexta supported 3Q23 earnings.